Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis
Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent pharmaceutical group for type 2 diabetes (T2D) treatment. Evidence indicates contradictory relationships between sodium-glucose cotransporter-2 inhibitors and bladder cancer (BC). Hence, this study aims to investigat...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Diabetic Nephropathy Prevention
2023-03-01
|
| Series: | Journal of Nephropathology |
| Subjects: | |
| Online Access: | https://nephropathol.com/PDF/jnp-12-e21444.pdf |
| _version_ | 1797828053344190464 |
|---|---|
| author | Mobin Mohammadtabar Alireza Fazeli Najmeh Parsai Zahra Aboulfathiyarmohammadyar Erfan Shafiei Mohamad Khaledi Elahe Zaremoghadam Ali Rahnama Sisakht Saeid Mohammadi Hossein Mardanparvar |
| author_facet | Mobin Mohammadtabar Alireza Fazeli Najmeh Parsai Zahra Aboulfathiyarmohammadyar Erfan Shafiei Mohamad Khaledi Elahe Zaremoghadam Ali Rahnama Sisakht Saeid Mohammadi Hossein Mardanparvar |
| author_sort | Mobin Mohammadtabar |
| collection | DOAJ |
| description | Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent pharmaceutical group for type 2 diabetes (T2D) treatment. Evidence indicates contradictory relationships between sodium-glucose cotransporter-2 inhibitors and bladder cancer (BC). Hence, this study aims to investigate the relationship between SGLT2 inhibitors and BC in patients with T2D. Materials and Methods: This study is a systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). International databases including Cochrane, Web of Science, Scopus, PubMed, and Google Scholar were conducted for searching with keywords and without time and language limitations. The reference searching stage continued upgrading until November, 2022. Data analysis was performed with STATA 14 software. The tests with P values lower than 0.05 were considered statistically significant. Results: The four reviewed studies with a sample size comprising 497 755 individuals indicated the impact of SGLT2 inhibitors on BC of patients with T2D (OR: 0.68; 95% CI: 0.37, 1.2). The effect of dapagliflozin, canagliflozin and empagliflozin administration on the incidence of BC among the T2D patients were (OR: 0.72; 95% CI: 0.39, 1.30), (OR: 0.53; 95% CI: 0.23, 1.20), and (OR: 0.51; 95% CI: 0.20, 1.28), respectively. Conclusion: The general conclusion of this study revealed that SGLT2 inhibitors did not increase the risk of BC in T2D patients. The analysis of subgroups also indicated that the administration of dapagliflozin, canagliflozin, and empagliflozin also did not increase the risk of BC in T2D patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID=CRD42023389014). |
| first_indexed | 2024-04-09T12:58:16Z |
| format | Article |
| id | doaj.art-7fa3dff1047045b3abc6f6947106b6d4 |
| institution | Directory Open Access Journal |
| issn | 2251-8363 2251-8819 |
| language | English |
| last_indexed | 2024-04-09T12:58:16Z |
| publishDate | 2023-03-01 |
| publisher | Society of Diabetic Nephropathy Prevention |
| record_format | Article |
| series | Journal of Nephropathology |
| spelling | doaj.art-7fa3dff1047045b3abc6f6947106b6d42023-05-13T10:58:18ZengSociety of Diabetic Nephropathy PreventionJournal of Nephropathology2251-83632251-88192023-03-01122e21444e2144410.34172/jnp.2023.21444jnp-21444Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysisMobin Mohammadtabar0Alireza Fazeli1Najmeh Parsai2Zahra Aboulfathiyarmohammadyar3Erfan Shafiei4Mohamad Khaledi5Elahe Zaremoghadam6Ali Rahnama Sisakht7Saeid Mohammadi8Hossein Mardanparvar9Department of Ophthalmology, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, IranDepartment of Medical Education, Medical Education Research Center, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Nursing, Faculty of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, IranStudent Committee Research, School of Pharmacy (Pharm D), Eastern Mediterranean University of North Cyprus, Famagusta, CyprusSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Nursing, Faculty of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, IranDepartment of Internal Medicine, School of Medicine, Birjand University of Medical Sciences, Birjand, IranStudent Research Committee, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, IranStudent Research Committee, School of Dentistry, European University of Georgia, Tibilisi, GeorgiaDepartment of Nursing, Faculty of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, IranIntroduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent pharmaceutical group for type 2 diabetes (T2D) treatment. Evidence indicates contradictory relationships between sodium-glucose cotransporter-2 inhibitors and bladder cancer (BC). Hence, this study aims to investigate the relationship between SGLT2 inhibitors and BC in patients with T2D. Materials and Methods: This study is a systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). International databases including Cochrane, Web of Science, Scopus, PubMed, and Google Scholar were conducted for searching with keywords and without time and language limitations. The reference searching stage continued upgrading until November, 2022. Data analysis was performed with STATA 14 software. The tests with P values lower than 0.05 were considered statistically significant. Results: The four reviewed studies with a sample size comprising 497 755 individuals indicated the impact of SGLT2 inhibitors on BC of patients with T2D (OR: 0.68; 95% CI: 0.37, 1.2). The effect of dapagliflozin, canagliflozin and empagliflozin administration on the incidence of BC among the T2D patients were (OR: 0.72; 95% CI: 0.39, 1.30), (OR: 0.53; 95% CI: 0.23, 1.20), and (OR: 0.51; 95% CI: 0.20, 1.28), respectively. Conclusion: The general conclusion of this study revealed that SGLT2 inhibitors did not increase the risk of BC in T2D patients. The analysis of subgroups also indicated that the administration of dapagliflozin, canagliflozin, and empagliflozin also did not increase the risk of BC in T2D patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID=CRD42023389014).https://nephropathol.com/PDF/jnp-12-e21444.pdfcancerneoplasmdiabetessglt2sodium-glucose cotransporter-2inhibitorsdapagliflozincanagliflozinempagliflozinbladder |
| spellingShingle | Mobin Mohammadtabar Alireza Fazeli Najmeh Parsai Zahra Aboulfathiyarmohammadyar Erfan Shafiei Mohamad Khaledi Elahe Zaremoghadam Ali Rahnama Sisakht Saeid Mohammadi Hossein Mardanparvar Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis Journal of Nephropathology cancer neoplasm diabetes sglt2 sodium-glucose cotransporter-2 inhibitors dapagliflozin canagliflozin empagliflozin bladder |
| title | Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis |
| title_full | Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis |
| title_fullStr | Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis |
| title_full_unstemmed | Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis |
| title_short | Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis |
| title_sort | association between sglt2 sodium glucose cotransporter 2 inhibitors and bladder cancer in individuals with type 2 diabetes a systematic review and meta analysis |
| topic | cancer neoplasm diabetes sglt2 sodium-glucose cotransporter-2 inhibitors dapagliflozin canagliflozin empagliflozin bladder |
| url | https://nephropathol.com/PDF/jnp-12-e21444.pdf |
| work_keys_str_mv | AT mobinmohammadtabar associationbetweensglt2sodiumglucosecotransporter2inhibitorsandbladdercancerinindividualswithtype2diabetesasystematicreviewandmetaanalysis AT alirezafazeli associationbetweensglt2sodiumglucosecotransporter2inhibitorsandbladdercancerinindividualswithtype2diabetesasystematicreviewandmetaanalysis AT najmehparsai associationbetweensglt2sodiumglucosecotransporter2inhibitorsandbladdercancerinindividualswithtype2diabetesasystematicreviewandmetaanalysis AT zahraaboulfathiyarmohammadyar associationbetweensglt2sodiumglucosecotransporter2inhibitorsandbladdercancerinindividualswithtype2diabetesasystematicreviewandmetaanalysis AT erfanshafiei associationbetweensglt2sodiumglucosecotransporter2inhibitorsandbladdercancerinindividualswithtype2diabetesasystematicreviewandmetaanalysis AT mohamadkhaledi associationbetweensglt2sodiumglucosecotransporter2inhibitorsandbladdercancerinindividualswithtype2diabetesasystematicreviewandmetaanalysis AT elahezaremoghadam associationbetweensglt2sodiumglucosecotransporter2inhibitorsandbladdercancerinindividualswithtype2diabetesasystematicreviewandmetaanalysis AT alirahnamasisakht associationbetweensglt2sodiumglucosecotransporter2inhibitorsandbladdercancerinindividualswithtype2diabetesasystematicreviewandmetaanalysis AT saeidmohammadi associationbetweensglt2sodiumglucosecotransporter2inhibitorsandbladdercancerinindividualswithtype2diabetesasystematicreviewandmetaanalysis AT hosseinmardanparvar associationbetweensglt2sodiumglucosecotransporter2inhibitorsandbladdercancerinindividualswithtype2diabetesasystematicreviewandmetaanalysis |